Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Axikin raises $3 million in financing
The financing was led by Sanderling Ventures of San Mateo, California. Additional investors include Mitsui & Co Venture Partners of New York. Axikin’s pipeline includes an advanced preclinical
The financing was led by Sanderling Ventures of San Mateo, California. Additional investors include Mitsui & Co Venture Partners of New York. Axikin’s pipeline includes an advanced preclinical
Gunnar Saelid, CEO of Lytix Biopharma, said: “The company has made significant progress in 2008, initiating full preclinical development activities for two important projects. LTX-109 is a novel
Dr Nisi is a prominent cardiologist, the chairman of the board and an attending physician at Westchester Square Medical Center and has been a clinical professor of medicine
Life Vessel of Newport Beach, California and Life Vessel of Santa Fe, New Mexico offer the exclusive and proprietary BioTech L3aser Pain management treatment protocols using an FDA
The agreement provides for R&D into acne formulations based on Skinvisible’s Invisicare technology and benzoyl peroxide (BPO) manufactured by Cambrex. In addition, the two companies will share marketing
The pen injector is being developed under a licensing agreement signed in January 2008 between the companies where Antares will supply a custom proprietary pen for two self-administered
Sander Deventer, Amsterdam Molecular Therapeutics’s (AMT) chief scientific officer and co-founder of the company, has been named CEO on an interim basis. The company has said that the
The study, at two academic departments of ophthalmology, is designed to assess the safety and efficacy of the Aquashunt and will enroll up to 20 patients with significantly
While performing heart bypass surgery, SPY-Q enables cardiac surgeons using Novadaq’s SPY imaging system to objectively measure increases in fluorescence by comparing pre- and post-bypass images, the company
The approval is based on data from two large, pivotal Phase III, multi-center, randomized, double-blind, placebo controlled trials, Phoenix 1 & 2, involving nearly 2,000 patients in whom